In 2014, MAPS spun out a separate division to immediate exploration and put together for an eventual FDA application, which it submitted at the conclusion of previous year. In early 2024, that offshoot was renamed Lykos Therapeutics.Concerns about safety troubles, Negative effects, and abuse are more likely to pop up for other psychedelics too, say